Prospective Follow-up Study for Patients who Completed Study ALX0681-C301 (HERCULES) to Evaluate Long-term Safety and Efficacy of Caplacizumab (Post-HERCULES)
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 29 Nov 2017
At a glance
- Drugs Caplacizumab (Primary) ; Caplacizumab (Primary)
- Indications Thrombotic thrombocytopenic purpura
- Focus Adverse reactions
- Sponsors Ablynx
- 29 Nov 2017 This trial has been completed in Germany (end date:2017-05-17).
- 09 Nov 2017 Planned End Date changed from 1 Jul 2020 to 1 Oct 2020.
- 09 Nov 2017 Planned primary completion date changed from 1 Jul 2020 to 1 Oct 2020.